tbuckley/cabot-search huggingface dataset:
Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis
Authors: Yichuan Pang, Li Su, Yao Fu, Fan Jia, Chenxi Zhang, Xiankun Cao, Wenxin He, Xueqian Kong, Jiake Xu, Jie Zhao, An Qin
Journal: Bioactive Materials (2020)

Breast cancer bone metastasis poses significant challenge for therapeutic strategies. Inside the metastatic environment, osteoclasts and tumor cells interact synergistically to promote cancer progression. In this study, the proprotein convertase furin is targeted due to its critical roles in both tumor cell invasion and osteoclast function. Importantly, the furin inhibitor is specifically delivered by bone targeting superparamagnetic iron oxide (SPIO) nanoparticles. Our in vitro and in vivo data demonstrate that this system can effectively inhibit both osteoclastic bone resorption and breast cancer invastion, leading to alleviated osteolysis. Therefore, the bone targeting & furin inhibition nanoparticle system is a promising therapeutic and diagnostic strategy for breast cancer bone metastasis.
Type A Aortic Dissection—Experience Over 5 Decades
Authors: Yuanjia Zhu, Bharathi Lingala, Michael Baiocchi, Jacqueline J. Tao, Veronica Toro Arana, Jason W. Khoo, Kiah M. Williams, Abd Al-Rahman Traboulsi, Hilary C. Hammond, Anson M. Lee, William Hiesinger, Jack Boyd, Philip E. Oyer, Edward B. Stinson, Bruce A. Reitz, R. Scott Mitchell, D. Craig Miller, Michael P. Fischbein, Y. Joseph Woo
Journal: Journal of the American College of Cardiology (2020)
Iatrogenic Lung Microembolism Resulted in Extraosseous Uptake of 99mTc-MDP
Authors: Lei Lei, Yan Deng, Haoyuan Ding, Wei Zhang
Journal: Clinical Nuclear Medicine (2020)

Abstract A 61-year-old woman diagnosed with left breast cancer underwent a bone scan for the evaluation of possible bone metastases. Multiple foci of elevated activity were noticed in the spine and pelvis. In addition, a focus of intense activity was observed in the right lung on the SPECT/CT images without corresponding anatomic abnormality.
746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
Authors: P. O'Donnell, M.D. Galsky, J.E. Rosenberg, D.P. Petrylak, A.V. Balar, B.A. McGregor, E. Heath, E.Y. Yu, D.I. Quinn, N.M. Hahn, M. Campbell, S-Y. Liang, J. Steinberg, Y. Loriot
Journal: Annals of Oncology (2020)

Locally advanced or metastatic urothelial carcinoma (la/mUC) is an incurable disease with poor overall survival (OS), particularly in patients (pts) who progress on or after platinum-containing chemotherapy (Pt-CC). While OS data following PD-1/PD-L1 inhibitor (i) and Pt-CC are limited, data in earlier lines (post-Pt-CC) show a 7.4 mo median (md) OS with a 30.7% 12 mo OS rate for taxanes/vinflunine (Bellmunt 2017). In Dec 2019, enfortumab vedotin (EV), a Nectin-4 directed antibody-drug conjugate comprised of a fully human monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E was granted accelerated approval in adult pts with la/mUC who previously received PD-1/PD-L1-i and Pt-CC in the neoadjuvant/adjuvant, la/m setting. Approval was based on data as of 01 Mar 2019 from EV-201 (NCT03219333) Cohort 1 (C1) showing an ORR of 44% and a manageable side effect profile. We present data on C1 OS and safety with an additional year of follow-up (fu). Pts in this open-label, multicenter study received EV 1.25 mg/kg on Days 1, 8, 15 of each 28-day cycle. The primary endpoint was confirmed ORR per RECIST 1.1 by BICR. Key secondary endpoints were OS, safety/tolerability, duration of response, and PFS. 125 pts received EV in C1 (md age 69 y; md 3 prior systemic therapies; 35% upper tract disease; 40% liver metastases). Md fu was 22.3 mo (range, 0.5-27.3+) and md OS was 12.4 mo (95% CI: 9.46, 15.57). OS rates at 12 and 18 mo were 50.4% and 34.2%, respectively. Md and maximum treatment (tx) duration were 4.6 mo and 27.3 mo (ongoing as of data cutoff), respectively. The most common tx-related AEs included alopecia (49.6%), fatigue (49.6%), and decreased appetite (44%). Tx-related AEs of interest included any skin reactions (51.2% all grade [AG], 12.8% ≥ G3), any peripheral neuropathy (50.4% AG, 3.2% ≥ G3), and any hyperglycemia (11.2% AG, 5.6% ≥ G3). OS from long-term fu of la/mUC pts who previously received PD-1/PD-L1-i and Pt-CC in EV-201 C1 is encouraging, with half of the pts alive at 12 mo and one-third alive at 18 mo; the safety of EV continues to be manageable in these pts with no new signals.
Specific Hypothalamic Neurons Required for Sensing Conspecific Male Cues Relevant to Inter-male Aggression
Authors: Ai-Xiao Chen, Jing-Jing Yan, Wen Zhang, Lei Wang, Zi-Xian Yu, Xiao-Jing Ding, Dan-Yang Wang, Min Zhang, Yan-Li Zhang, Nan Song, Zhuo-Lei Jiao, Chun Xu, Shu-Jia Zhu, Xiao-Hong Xu
Journal: Neuron (2020)
CN39 Depression and its impact on quality of life in lung cancer patients with comorbid diabetes type 2
Authors: M. Lavdaniti, P. Charitopoulos, D-A. Owens, I. Chatzi, E. Vlachou, A. Chatzinikolaou, A. Ouzouni, K. Kazakos
Journal: Annals of Oncology (2020)
68Ga-FAPI and 18F-FDG PET/CT Images in a Patient With Extrapulmonary Tuberculosis Mimicking Malignant Tumor
Authors: Bingxin Gu, Zhiguo Luo, Xinhong He, Jian Wang, Shaoli Song
Journal: Clinical Nuclear Medicine (2020)

Abstract Extrapulmonary tuberculosis (TB) is difficult to diagnose. Here, we report a case of extrapulmonary TB in a 68-year-old woman presented with mental fatigue, poor appetite, and weight loss. 18 F-FDG PET/CT revealed elevated 18 F-FDG uptake in the left inferior cervical, left supraclavicular, mediastinal, and splenic hilum lymph nodes and spleen, which were suspected of malignant tumor. To further differentiate benign and malignant diseases, 68 Ga-FAPI PET/CT was performed. 68 Ga-FAPI PET/CT also showed intense 68 Ga-FAPI uptake in the previously mentioned FDG-avid lesions. However, biopsy of the left supraclavicular lymph node demonstrated the presence of TB.
12P Genome mining-aided biosynthesis overcomes Temozolomide-resistant glioblastoma via negatively regulating cIAP-mediated degradation of PACS2 and ER-mitochondria contact sites
Authors: L. Chen, Z-Y. Li, W-L. Liu, G-D. Huang, Y. Wu, W-P. Li
Journal: Annals of Oncology (2020)
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Authors: Paul Sargos, Sylvie Chabaud, Igor Latorzeff, Nicolas Magné, Ahmed Benyoucef, Stéphane Supiot, David Pasquier, Menouar Samir Abdiche, Olivier Gilliot, Pierre Graff-Cailleaud, Marlon Silva, Philippe Bergerot, Pierre Baumann, Yazid Belkacemi, David Azria, Meryem Brihoum, Michel Soulié, Pierre Richaud
Journal: The Lancet Oncology (2020)
805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment
Authors: A.R. Clamp, E.C. James, I. McNeish, A. Dean, J-W. Kim, D.M. O'Donnell, J. Hook, D. Gallardo-Rincon, C. Coyle, S. Blagden, J.D. Brenton, R. Naik, T.J. Perren, S. Sundar, A. Cook, J. Badrock, A.M. Swart, M.K. Parmar, R.S. Kaplan, J.A. Ledermann
Journal: Annals of Oncology (2020)
Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis
Authors: Min Yan Shi, In Hyuk Bang, Chang Yeob Han, Dae Ho Lee, Byung-Hyun Park, Eun Ju Bae
Journal: Theranostics (2020)

Rationale: Statin, the most widely used medication in lowering cholesterol, is also associated with increased risk of type 2 diabetes, but its molecular basis remains unclear. Methods: Mice were injected intraperitoneally with statins alone or in combination with sirtuin (Sirt) 6 activator, and blood glucose levels were measured. Liver tissues from patients with statin use were analyzed for the expression of Sirt6. Results: Statin treatment up-regulated the hepatic expression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, which was prevented by Sirt6 overexpression. Mechanistically, statin directly repressed Sirt6 expression by induction of microRNA (miR)-495, a novel inhibitor of Sirt6. Pathway analysis for predicted target genes of miR-495 recognized forkhead box protein (Fox)O1 as a key downstream signaling of Sirt6. Statin treatment increased the acetylation and protein stability of FoxO1, which was suppressed by Sirt6 overexpression. Inhibiting miR-495 recovered Sirt6 levels, blocking the ability of statin to increase FoxO1 mediated gluconeogenesis, and thus confirming the role of the miR-495/Sirt6/FoxO1 pathway in controlling gluconeogenesis. Moreover, the Sirt6 activator MDL801 prevented gluconeogenesis and hyperglycemia induced by statin in mice. Equally noteworthy was that human liver tissues obtained from statin users showed a significant decrease in Sirt6 protein levels compared to those of non-users. Conclusion: Statin induces miR-495 to suppress Sirt6 expression, which leads to enhancement of FoxO1-mediated hepatic gluconeogenesis. Thus, Sirt6 activation may offer a promising strategy for preventing statin-induced hyperglycemia.
1369P EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study
Authors: T. Tian, X. Fu, W. Wang, L. Jiang, X. Liang, Z. Ruan, Y. Yao
Journal: Annals of Oncology (2020)
On-demand degradable embolic microspheres for immediate restoration of blood flow during image-guided embolization procedures
Authors: Hyunjun Choi, Bongseo Choi, Bo Yu, Weiguo Li, Monica M. Matsumoto, Kathleen R. Harris, Robert J. Lewandowski, Andrew C. Larson, Samdeep K. Mouli, Dong-Hyun Kim
Journal: Biomaterials (2020)
1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC)
Authors: J. Hernando, V. Tarasova, M.I. Hu, E.J. Sherman, M.S. Brose, B. Robinson, M. Tahara, L.J. Wirth, A. Sashegyi, V. Soldatenkova, B.K. Lin, J. Wright, A.O. Hoff, S. Leboulleux, R. Elisei, J. Capdevila
Journal: Annals of Oncology (2020)
947P Association between genetic variants and cisplatin nephrotoxicity: A genome-wide approach
Authors: Z. Zazuli, W. Xu, S. Vijverberg, R. Masereeuw, M. Mirshams, K. Khan, B. Ordonez-Perez, S.H. Huang, A. Spreafico, A.R. Hansen, D. Goldstein, J. de Almeida, S. Bratman, A. Hope, B. Carleton, A-H. Maitland-van der Zee, G. Liu
Journal: Annals of Oncology (2020)
Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases
Authors: Xiaohe Li, Yinshan Fang, Dingyuan Jiang, Yingying Dong, Yingying Liu, Si Zhang, Jiasen Guo, Chao Qi, Chenjing Zhao, Fangxin Jiang, Yueyue Jin, Jing Geng, Cheng Yang, Hongkai Zhang, Bin Wei, Jiurong Liang, Chen Wang, Huaping Dai, Honggang Zhou, Dianhua Jiang, Wen Ning
Journal: Molecular Therapy (2020)

Follistatin-like 1 (FSTL1) is a matricellular protein that is upregulated during development and disease, including idiopathic pulmonary fibrosis (IPF), keloid, and arthritis. The profibrotic and pro-inflammatory roles of FSTL1 have been intensively studied during the last several years, as well as in this report. We screened and identified epitope-specific monoclonal neutralizing antibodies (nAbs) to functionally block FSTL1. FSTL1 nAbs attenuated bleomycin-induced pulmonary and dermal fibrosis in vivo and transforming growth factor (TGF)-β1-induced dermal fibrosis ex vivo in human skin. In addition, FSTL1 nAbs significantly reduced existing lung fibrosis and skin fibrosis in experimental models. FSTL1 nAbs exerted their potent antifibrotic effects via reduced TGF-β1 responsiveness and subsequent myofibroblast activation and extracellular matrix production. We also observed that FSTL1 nAbs attenuated the severity of collagen-induced arthritis in mice, which was accompanied by reduced inflammatory responses in vitro. Our findings suggest that FSTL1 nAbs are a promising new therapeutic strategy for the treatment of multiple organ fibrosis and systemic autoimmune diseases. Follistatin-like 1 (FSTL1) is a matricellular protein that is upregulated during development and disease, including idiopathic pulmonary fibrosis (IPF), keloid, and arthritis. The profibrotic and pro-inflammatory roles of FSTL1 have been intensively studied during the last several years, as well as in this report. We screened and identified epitope-specific monoclonal neutralizing antibodies (nAbs) to functionally block FSTL1. FSTL1 nAbs attenuated bleomycin-induced pulmonary and dermal fibrosis in vivo and transforming growth factor (TGF)-β1-induced dermal fibrosis ex vivo in human skin. In addition, FSTL1 nAbs significantly reduced existing lung fibrosis and skin fibrosis in experimental models. FSTL1 nAbs exerted their potent antifibrotic effects via reduced TGF-β1 responsiveness and subsequent myofibroblast activation and extracellular matrix production. We also observed that FSTL1 nAbs attenuated the severity of collagen-induced arthritis in mice, which was accompanied by reduced inflammatory responses in vitro. Our findings suggest that FSTL1 nAbs are a promising new therapeutic strategy for the treatment of multiple organ fibrosis and systemic autoimmune diseases.
1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
Authors: M.G. Krebs, F. De Braud, S. Siena, A. Drilon, R.C. Doebele, M.R. Patel, B.C. Cho, S.V. Liu, M-J. Ahn, C-H. Chiu, A.F. Farago, C-C. Lin, C.S. Karapetis, Y-C. Li, F. Barlesi, B. Simmons, B. Pitcher, R. Dziadziuszko
Journal: Annals of Oncology (2020)
864P Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer
Authors: A. Leary, P. Estévez-García, R. Sabatier, L. Fariñas-Madrid, J.A. Pérez-Fidalgo, M. Romeo, M.P. Barretina Ginesta, M. Gil-Martin, E. Garralda, J. Rodon, J.M. Lizcano, P. Muñoz Guardiola, H. Pérez-Montoyo, M. Yeste-Velasco, M. Cortal, C. Domènech, J. Alfon, I.L. Ray-Coquard, A. Oaknin
Journal: Annals of Oncology (2020)
63P Multicentre match-paired analysis of advanced biliary cancer (ABC) long-term survivors: The BILONG study
Authors: F. Caputo, F. Gelsomino, A. Spallanzani, E. Pettorelli, S. Benatti, M. Ghidini, G. Grizzi, M. Ratti, V. Merz, C. Messina, R. Tonelli, G. Luppi, D. Melisi, M. Dominici, M. Salati
Journal: Annals of Oncology (2020)
248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Authors: S. Loibl, P. Rastogi, S. Seiler, C. Jackisch, P.C. Lucas, C. Denkert, A. Poklepovic, F. Moreno, E.P. Mamounas, V. Nekljudova, Y. Lin, N. Wolmark, C. Geyer
Journal: Annals of Oncology (2020)
Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs) ameliorate hepatic stellate cells activation in vitro and acute liver injury in vivo
Authors: Dhadhang Wahyu Kurniawan, Richell Booijink, Lena Pater, Irene Wols, Aggelos Vrynas, Gert Storm, Jai Prakash, Ruchi Bansal
Journal: Journal of Controlled Release (2020)

Liver diseases are the growing health problem with no clinically approved therapy available. Activated hepatic stellate cells (HSCs) are the key driver cells responsible for extracellular matrix deposition, the hallmark of liver fibrosis. Fibroblast growth factor 2 (FGF2) has shown to possess anti-fibrotic effects in fibrotic diseases including liver fibosis, and promote tissue regeneration. Among the fibroblast growth factor receptors (FGFRs), FGF2 interact primarily with FGFR1, highly overexpressed on activated HSCs, and inhibit HSCs activation. However, FGF2 poses several limitations including poor systemic half-life and stability owing to enzymatic degradation. The aim of this study is to improve the stability and half-life of FGF2 thereby improving the therapuetic efficacy of FGF2 for the treatment of liver fibrosis. We found that FGFR1-3 mRNA levels were overexpressed in cirrhotic human livers, while FGFR1c, 2c, 3c, 4 and FGF2 mRNA levels were overexpressed in TGFβ-activated HSCs (LX2 cells) and FGFR1 protein expression was highly increased in TGFβ-activated HSCs. Treatment with FGF2 inhibited TGFβ-induced HSCs activation, migration and contraction in vitro. FGF2 was conjugated to superparamagnetic iron-oxide nanoparticles (SPIONs) using carbodiimide chemistry, and the resulting FGF2-SPIONs were confirmed by dynamic light scattering (DLS), zeta potential, dot-blot analysis and Prussian Blue iron-staining. In vitro, treatment with FGF2-SPIONs evidenced increased therapeutic effects (attenuated TGFβ-induced HSCs activation, migration and contraction) of FGF2 in TGFβ-activated HSCs and ameliorated early liver fibrogenesis in vivo in acute carbon tetrachloride (CCl4)-induced liver injury mouse model. In contrast, free FGF2 showed no significant effects in vivo. Altogether, this study presents a promising therapeutic approach using FGF2-SPIONs for the treatment of liver fibrosis.
1453P Safety and efficacy of vactosertib, a TGF-βR1 kinase inhibitor, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma
Authors: M. Jung, C-K. Lee, H.S. Kim, C-Y. Ock, J.B. Bae, J.K. Lee, D.W. Kang, S. Hwang, K.B. Hahm, S-J. Kim, H.C. Chung, S.Y. Rha
Journal: Annals of Oncology (2020)
1343P Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)
Authors: G.D.M. Veerman, C.M.J. Steendam, S.L. Koolen, E. Oomen-de Hoop, A-M.C. Dingemans, J.G.J.V. Aerts, R.H. Mathijssen
Journal: Annals of Oncology (2020)
1526P First and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort
Authors: E. Pijnappel, W.P.M. Dijksterhuis, L. van der Geest, J. de vos-Geelen, J.W.B. de Groot, A.J. ten Tije, M. Homs, G-J. Creemers, N. Haj Mohammad, H.W.M. van Laarhoven, H. Wilmink
Journal: Annals of Oncology (2020)
Gadobutrol-Enhanced Cardiac Magnetic Resonance Imaging for Detection of Coronary Artery Disease
Authors: Andrew E. Arai, Jeanette Schulz-Menger, Daniel Berman, Heiko Mahrholdt, Yuchi Han, W. Patricia Bandettini, Matthias Gutberlet, Arun Abraham, Pamela K. Woodard, Joseph B. Selvanayagam, Gerry P. McCann, Christian Hamilton-Craig, U. Joseph Schoepf, Ru San Tan, Christopher M. Kramer, Matthias G. Friedrich, Daniel Haverstock, Zheyu Liu, Guenther Brueggenwerth, Claudia Bacher-Stier, Marta Santiuste, Dudley J. Pennell, Dudley Pennell, Jeanette Schulz-Menger, Heiko Mahrholdt, Matthias Gutberlet, Ulrich Kramer, Giso von der Recke, Kai Nassenstein, Christoph Tillmanns, Matthias Taupitz, Gregor Pache, Oliver Mohrs, Joachim Lotz, Sung-Min Ko, Ki Seok Choo, Yon Mi Sung, Joon-Won Kang, Stefano Muzzarelli, Uma Valeti, Gerry McCann, Sukumaran Binukrishnam, Pierre Croisille, Alexis Jacquier, Brett Cowan, Andrew Arai, Daniel Berman, Dipan Shah, W. Patricia Bandettini, Yuchi Han, Pamela Woodard, Ryan Avery, Joseph Schoepf, James Carr, Christopher Kramer, Scott Flamm, Mukesh Harsinghani, Stamitios Lerakis, Raymond Kim, Subha Raman, Francois Marcotte, Ali Islam, Matthias Friedrich, Arun Abraham, Joseph Selvanayagam, Christian Hamilton-Craig, Woon Kit Chong, Li San Lynette Teo, Ru San Tan
Journal: Journal of the American College of Cardiology (2020)

Gadolinium-based contrast agents were not approved in the United States for detecting coronary artery disease (CAD) prior to the current studies. The purpose of this study was to determine the sensitivity and specificity of gadobutrol for detection of CAD by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging. Two international, single-vendor, phase 3 clinical trials of near identical design, "GadaCAD1" and "GadaCAD2," were performed. Cardiovascular magnetic resonance (CMR) included gadobutrol-enhanced first-pass vasodilator stress and rest perfusion followed by LGE imaging. CAD was defined by quantitative coronary angiography (QCA) but computed tomography coronary angiography could exclude significant CAD. Because the design and results for GadaCAD1 (n = 376) and GadaCAD2 (n = 388) were very similar, results were summarized as a fixed-effect meta-analysis (n = 764). The prevalence of CAD was 27.8% defined by a ≥70% QCA stenosis. For detection of a ≥70% QCA stenosis, the sensitivity of CMR was 78.9%, specificity was 86.8%, and area under the curve was 0.871. The sensitivity and specificity for multivessel CAD was 87.4% and 73.0%. For detection of a 50% QCA stenosis, sensitivity was 64.6% and specificity was 86.6%. The optimal threshold for detecting CAD was a ≥67% QCA stenosis in GadaCAD1 and ≥63% QCA stenosis in GadaCAD2. Vasodilator stress and rest myocardial perfusion CMR and LGE imaging had high diagnostic accuracy for CAD in 2 phase 3 clinical trials. These findings supported the U.S. Food and Drug Administration approval of gadobutrol-enhanced CMR (0.1 mmol/kg) to assess myocardial perfusion and LGE in adult patients with known or suspected CAD.
Patients with early-onset rectal cancer aged 40 year or less have similar oncologic outcomes to older patients despite presenting in more advanced stage; A retrospective cohort study
Authors: Sameh Hany Emile, Hossam Elfeki, Mostafa Shalaby, Saleh Elbalka, Islam Hany Metwally, Mohamed Abdelkhalek
Journal: International Journal of Surgery (2020)
Abstract 18686: Normalization of Hemodynamic Responses as a Final Goal of Balloon Pulmonary Angioplasty in Patients With CTEPH
Authors: Tatsuo Aoki, Koichiro Sugimura, Shunsuke Tatebe, Saori Yamamoto, Nobuhiro Yaoita, Haruka Sato, Katsuya Kozu, Ryo Konno, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa
Journal: Circulation (2017)

Background: Balloon pulmonary angioplasty (BPA) ameliorates hemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) at rest without any vasodilators. However,...
724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)
Authors: C. Thibault, R.T. Elaidi, A. Fléchon, L. Albiges, C. Joly, P. Barthélémy, M. Gross Goupil, C.M. Chevreau, F. Joly, F. Rolland, B. Laguerre, G. Gravis, M. Brihoum, M-O. Timsit, N. Pecuchet, Y. Allory, S. Oudard
Journal: Annals of Oncology (2020)
1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
Authors: M. Hauchecorne, C. Baldini, S. Foulon, A. Bayle, B. Gachot, F. Pommeret, C. Willekens, F. Griscelli, F. Netzer, C. Balleyguier, S. Ammari, F. André, F. Scotté, B. Besse, J-C. Soria, F. Barlesi, L. Albiges
Journal: Annals of Oncology (2020)
1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
Authors: S. Lu, Y. Yu, X. Yu, Y. Hu, Z. Ma, X. Li, W. Zhuang, Y. Liu, W. Li, J. Cui, D. Wang, W. Liao, M. Wang, J. Zhou, Z. Wang, Y. Sun, J. Gao, Y. Bao, L. Liang, J. Wang
Journal: Annals of Oncology (2020)
278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients
Authors: B. Krastev, R. Rai, I. Bulat, M. Maglakelidze, C. Murias, H-T. Arkenau, R.D. Baird, A.M. Wardley, R. Roylance, A. Crijanovschi, M. Gogiladze, W. Tao, A.P. Beelen, J.A. Sorrentino
Journal: Annals of Oncology (2020)